Efficacy News and Research

RSS

Researchers study new drug and indications for heated chemotherapy treatment

Studies have shown that surgery combined with Intraperitoneal Hyperthermic Chemotherapy (IPHC) can improve survival rates for select patients with peritoneal carcinoma (cancer of the lining of the abdominal cavity) that has spread from colorectal or appendix cancer.

17 Mar 2008

Modified virus vaccine shows promise in mouse model of breast cancer

Researchers have shown that vaccinating mice with a modified form of a virus containing proteins from breast cancer cells can kill large breast cancer tumors and tumors that have spread to the lungs.

17 Mar 2008

Lilly and Transition Therapeutics announce licensing and collaboration agreement

Eli Lilly and Company and Transition Therapeutics Inc. has announced that the two companies have entered into a licensing and collaboration agreement granting Lilly exclusive worldwide rights to develop and commercialize Transition's gastrin based therapies, including the lead compound TT-223, which is currently in early Phase II testing.

14 Mar 2008

AstraZeneca completes enrollment in phase III studies of cancer drug vandetanib

AstraZeneca has announced that it has completed patient enrollment in two pivotal Phase III studies for vandetanib, the company's investigational, once-daily oral anti-cancer drug, for the second-line treatment of non-small cell lung cancer (NSCLC).

13 Mar 2008

Researchers may have found test for depression

Researchers from the University of Illinois at Chicago College of Medicine have discovered that a change in the location of a protein in the brain could serve as a biomarker for depression, allowing a simple, rapid, laboratory test to identify patients with depression and to determine whether a particular antidepressant therapy will provide a successful response.

12 Mar 2008

New discovery could change future diagnosis and therapy of depression

12 Mar 2008

Myostatin shows promise for muscular dystrophy

Myostatin, a protein that blocks muscle growth, has shown promising results as a potential therapeutic target for treating muscular dystrophy in animal studies, where its inhibition led to increased muscle mass and strength.

12 Mar 2008

Cervarix shows long-term protection from cervical cancer

New data demonstrate that GlaxoSmithKline's cervical cancer candidate vaccine, CERVARIX provides significant protection for women against the four most common cancer- causing human papillomavirus types for nearly six and a half years, the longest duration of protection reported to date.

12 Mar 2008

Combined therapeutic approach of stenting and photodynamic therapy improves survival in late stage liver cancer patients

A combined therapeutic approach of stenting and photodynamic therapy may improve survival rates for patients suffering from advanced liver bile duct cancer, according to a study published this month in Clinical Gastroenterology and Hepatology , the official journal of the American Gastroenterological Association (AGA) Institute.

12 Mar 2008

New diagnostic tool detects and monitors bladder cancer

Medical University of South Carolina (MUSC) Foundation for Research and Development announced a promising new diagnostic tool to detect and monitor bladder cancer.

12 Mar 2008

Warnings over DIY health tests

Leading health experts in Britain have expressed their concern about the boom in tests and scans for the "worried well".

12 Mar 2008

Adapting drug dosing to body size

University of Queensland researchers are leading the charge in adapting drug dosing to a society that is changing shape.

11 Mar 2008

Femara helps protect against return of breast cancer after completing Tamoxifen therapy

Women may reduce the risk of their breast cancer returning by starting treatment with Femara (letrozole tablets) anywhere from one to seven years after finishing tamoxifen therapy, according to a new analysis published in the Journal of Clinical Oncology.

11 Mar 2008

Pandemic influenza could be mitigated if measures were implemented quickly

An outbreak of pandemic influenza in the U.S. could be mitigated with prompt implementation of social-distancing measures combined with antiviral treatment and prophylaxis until a vaccine is available, according to new findings published in the online Early Edition of PNAS.

10 Mar 2008

London School of Hygiene and Tropical Medicine receives new Gates funding to fight disease

The London School of Hygiene & Tropical Medicine (LSHTM) has been awarded grant funding totalling $46.4 million from the Bill and Melinda Gates Foundation (BMGF) and $12.7 million from other partners, to help find new and effective ways of treating and preventing malaria, tuberculosis (TB) and HIV/AIDS.

10 Mar 2008

Bioniche receives fast track for bladder cancer therapy

Bioniche Life Sciences Inc. has announced that it has received notice from the U.S. Food and Drug Administration (FDA) that its therapy for first-line non-muscle-invasive bladder cancer meets the criteria for Fast Track designation.

6 Mar 2008

Experimental cancer drug MI-219 promising in preclinical studies

Researchers have long searched for a novel cancer drug that activates a certain protein to kill tumor cells.

4 Mar 2008

Cause of depression and anxiety unknown not chemical

The theory that depression is caused by a chemical imbalance is often presented in the media as fact even though there is little scientific evidence to support it, according to a new study co-authored by a Florida State University visiting lecturer.

4 Mar 2008

Predicting microbicide use in women

Using a new tool designed to measure a woman's willingness to use a microbicide (topical gels designed to prevent the sexual transmission of HIV), researchers at The Miriam Hospital and Brown University found that women who have used protective methods in the past, and those with casual sexual partners were more willing to use a microbicide compared to their peers.

4 Mar 2008

FDA approves Aloxi injection for prevention of postoperative nausea and vomiting

Eisai Corporation of North America, its U.S. subsidiary, MGI PHARMA, INC., and Helsinn Healthcare SA today announced that the U.S. Food and Drug Administration (FDA) has approved Aloxi (palonosetron hydrochloride) injection for the prevention of postoperative nausea and vomiting (PONV) for up to 24 hours following surgery.

4 Mar 2008